George Philips, M.D., M.B.B.S., M.P.H.
Associate Professor of Medicine
Research Program: Clinical Research
VCC Membership Level: Full Member
Contact Information
Given E-214
89 Beaumont Avenue
University of Vermont
Burlington, VT 05405
ph: (802) 656-5413
f: (802) 656-5493
george.philips@vtmednet.org
Biography
Dr. Philips completed his residency in internal medicine and a fellowship in Hematology/Medical Oncology at the University of Colorado Health Sciences Center in Denver, a National Cancer Institute designated cancer center. After completing a Masters in Public Health at Harvard University in 1999, Dr. Philips accepted a position at the University of Vermont and Fletcher Allen Health Care to develop the field of genitourinary oncology (prostate, kidney, bladder and testicular cancer) through collaborations with urologists and radiation oncologists. His efforts included establishment of a genitourinary tumor conference to promote high quality multidisciplinary patient care, and founding an annual urologic cancer symposium. Since 2006, Dr Philips has been involved in the development of the lung cancer multidisciplinary program and participates as a medical oncologist in the lung multidisciplinary tumor board and clinic. Dr. Philips is currently an associate professor at the University of Vermont College of Medicine and a member of the Vermont Cancer Center. He is the program director of the fully accredited Hematology-Oncology fellowship training program whose graduates are all Board Certified in Hematology and Medical Oncology and have successfully pursued clinical and academic careers across the United States.
Research
Dr. Philips' research interests focus on cancer prevention and treatment. He is the principal investigator of the Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Vermont. His primary area of interest is in conducting clinical trials for genitourinary cancers and lung cancer. He participates in national clinical trials through the Cancer and Leukemia Group B, a National Cancer Institute sponsored cancer clinical trials cooperative group.
Recent Publications
Philips G, Sanford B, Halabi S, Bajorin D, Small EJ .A Phase II Trial of Cisplatin (C), Fixed-Dose Rate Gemcitabine (G) and Gefitinib for Advanced Urothelial Tract Carcinoma: Results of Cancer and Leukemia Group B (CALGB) 90102. Br J Urol International 2008 ;101(1):20-5
D'Amico AV, Halabi S, Tempany C, Titelbaum D, Philips G. et al. Tumor Volume Changes on 1.5 Tesla Endorectal MRI During Neoadjuvant Androgen Suppression Therapy for Higher-Risk Prostate Cancer and Recurrence in Men Using Radiation Therapy. Results of the Phase II CALGB 9682 Study. Int J Radiation Oncology Biol Phys. 2007 Nov 23
Philips G, Reinier K, Ashikaga T Luebbers R. Attitudes and beliefs of primary care physicians regarding prostate and colorectal cancer screening in a rural state. J Cancer Educ. 2005;20:167-72.
Eneman J, Philips G. Cancer Management and Chemotherapy Use in Patients with End-Stage Renal Disease. Oncology 2005; 19: 1199-1212.
Padmanabhan V, Callas P, Trainer TD, Philips G, Aliesky H, Beatty BG. DNA Replication Regulation Protein MCM7 as a Marker of Proliferation in Prostate Cancer. J Clin Pathol. 2004 Oct;57(10):1057-62.
Small EJ, Halabi S, Dalbagni G, Pruthi R, Philips G, Edelman M, Bajorin D. Overview of Bladder Cancer Trials in the Cancer and Leukemia Group B. Cancer 2003;97(8 Suppl):2090-8
Other Key Publications
Picus J, Halabi S, Hussain A, Philips G, Kaplan E, Small E, Vogelzang N. Efficacy of Peripheral Androgen Blockade on Prostate Cancer: Initial Results of CALGB 9782. Proc of ASCO 2002; 21: 182a.
Paskulin GA, Philips G, Morgan R, Sandberg A, Richkind K, Borovik C, McGavran L, Rabinovich N, Dietz-Band J, Erickson P, Drabkin H, Varella-Garcia M. Pre-clinical evaluation of probes to detect t(8;21) AML minimal residual disease by fluorescence in situ hybridization. Genes Chrom Cancer 1998 21: 144-151.
